



Text Mining in der biomedizinischen Forschung

Ulf Leser, Humboldt-Universität zu Berlin





Case Report

- Patient with pneumonia and cough
- Normal dosage of codeine
- Patient not responding any more at day 4
- What's going on?
 - PubMed „Codeine intoxication“ -> [70 abstracts](#)
 - Aren't there better ways?

Case report from Univ. Hospital Geneva, thanks to Christian Meisel, Roche

AliBaba (Plake et al. 2006, Hakenberg et al. 2010)





Information

Objects Texts

- CYP2D6
 - Species (2)
 - Diseases (1)
- D(2)
- IMP
- Mat
- Monoamine oxidase
- OXY
- SRI
- TNS
- tryptase
- Drugs (22)
 - acetylcysteine
 - alcohol
 - amitriptyline
 - barbiturates

Proteins: [CYP2D6](#)

Textual Evidence

[PMID:15625333](#)

Codeine intoxication associated with ultrarapid **CYP2D6** metabolism.

Codeine is bioactivated by **CYP2D6** into **morphine**, which then undergoes further glucuronidation.

CYP2D6... showed that

Tree: Feedback mode

What we Need to do

Z-100 is an arabinomannan extracted from *Mycobacterium tuberculosis* that has various immunomodulatory activities, such as the induction of interleukin 12, interferon gamma (IFN-gamma) and beta-chemokines. The effects of Z-100 on human immunodeficiency virus type 1 (HIV-1) replication in human monocyte-derived macrophages (MDMs) are investigated in this paper. In MDMs, Z-100 markedly suppressed the replication of not only macrophage-tropic (M-tropic) HIV-1 strain (HIV-1JR-CSF), but also HIV-1 pseudotypes that possessed amphotropic Moloney murine leukemia virus or vesicular stomatitis virus G envelopes. Z-100 was found to inhibit HIV-1 expression, even when added 24 h after infection. In addition, it substantially inhibited the expression of the pNL43lucDeltaenv vector (in which the env gene is defective and the nef gene is replaced with the firefly luciferase gene) when this vector was transfected directly into MDMs. These findings suggest that Z-100 inhibits virus replication, mainly at HIV-1 transcription. However, Z-100 also downregulated expression of the cell surface receptors CD4 and CCR5 in MDMs, suggesting some inhibitory effect on HIV-1 entry. Further experiments revealed that Z-100 induced IFN-beta production in these cells, resulting in induction of the 16-kDa CCAAT/enhancer binding protein (C/EBP) beta transcription factor that represses HIV-1 long terminal repeat transcription. These effects were alleviated by SB 203580, a specific inhibitor of p38 mitogen-activated protein kinases (MAPK), indicating that the p38 MAPK signalling pathway was involved in Z-100-induced repression of HIV-1 replication in MDMs. These findings suggest that Z-100 might be a useful immunomodulator for control of HIV-1 infection.

Find Entities

Z-100 is an *arabinomannan* extracted from *Mycobacterium tuberculosis* that has various immunomodulatory activities, such as the induction of **interleukin 12**, **interferon gamma (IFN-gamma)** and beta-chemokines. The effects of *Z-100* on **human immunodeficiency virus type 1 (HIV-1)** replication in **human monocyte-derived macrophages (MDMs)** are investigated in this paper. In **MDMs**, *Z-100* markedly suppressed the replication of not only macrophage-tropic (M-tropic) **HIV-1** strain (**HIV-1JR-CSF**), but also **HIV-1** pseudotypes that possessed amphotropic **Moloney murine leukemia virus** or **vesicular stomatitis virus G** envelopes. *Z-100* was found to inhibit **HIV-1** expression, even when added 24 h after infection. In addition, it substantially inhibited the expression of the pNL43lucDeltaenv vector (in which the *env* gene is defective and the *nef* gene is replaced with the *firefly luciferase* gene) when this vector was transfected directly into **MDMs**. These findings suggest that *Z-100* inhibits virus replication, mainly at **HIV-1 transcription**. However, *Z-100* also downregulated expression of the **cell surface** receptors **CD4** and **CCR5** in **MDMs**, suggesting some inhibitory effect on **HIV-1** entry. Further experiments revealed that *Z-100* induced **IFN-beta** production in these cells, resulting in induction of the 16-kDa **CCAAT/enhancer binding protein (C/EBP) beta transcription factor** that represses **HIV-1** long terminal repeat **transcription**. These effects were alleviated by SB 203580, a specific inhibitor of **p38 mitogen-activated protein kinases (MAPK)**, indicating that the **p38 MAPK** signalling pathway was involved in *Z-100*-induced repression of **HIV-1** replication in **MDMs**. These findings suggest that *Z-100* might be a useful immunomodulator for control of **HIV-1** infection.

Normalize Entities

Tax: 1773


Entrez: 3458

Z-100 is an *arabinomannan* extracted from *Mycobacterium tuberculosis* that has various immunomodulatory activities, Tax: 9606 action of *interleukin 12*, *interferon gamma* (*IFN-gamma*) and beta-chemokines. The effects of *Z-100* on UMLS: C0001175 *virus type 1* (*HIV-1*) replication in *human monocyte-derived* are investigated in this paper. In *MDMs*, *Z-100* markedly suppressed the replication of not only macrophage-tropic (M-tropic) *HIV-1* strain (*HIV-1JR-CSF*), but also *HIV-1* pseudotypes that possessed amphotropic *Moloney murine leukemia virus* or *vesicular stomatitis virus G* envelopes. *Z-100* was found to inhibit *HIV-1* expression, even when added 24 h after infection. In addition, it substantially inhibited the expression of the pNL43lucDeltaenv vector (in which the *env* gene is defective) GO:0009986 placed with the *firefly luciferase* gene) when this vector was transfected into *MDMs*. These findings suggest that *Z-100* inhibits virus replication, mainly at *HIV-1* transcription. However, *Z-100* also downregulated expression of the cell surface receptors *CD4* and *CCR5* in *MDMs*, suggesting some inhibitory effect on *HIV-1* entry. Further experiments revealed that *Z-100* induced *IFN-beta* production in these cells, resulting in induction of the 16-kDa *CCAAT/enhancer binding protein* (*C/EBP*) *beta transcription factor* that represses *HIV-1* long terminal repeat transcription. These effects were alleviated by SB 203580, a specific inhibitor of *p38 mitogen-activated protein kinases* (*MAPK*), indicating that the *p38 MAPK* signalling pathway was involved in *Z-100*-induced repression of *HIV-1* replication in *MDMs*. These findings suggest that *Z-100* might be a useful immunomodulator for control of *HIV-1* infection.

Find Relationships

Z-100 is an *arabinomannan* derived from *Mycobacterium tuberculosis* that has various immunomodulatory activities. **Z-100** induces the induction of **interleukin 12, interferon gamma (IFN-gamma)** and beta-chemokines. The effects of **Z-100** on **human immunodeficiency virus type 1 (HIV-1)** replication in **human monocyte-derived macrophages (MDMs)** are investigated in this paper. In **MDMs**, **Z-100** markedly suppressed the replication of not only macrophage-tropic (M-tropic) **HIV-1** strain (**HIV-1JR-CSF**), but also **HIV-1** pseudotypes that possessed amphotropic envelopes. **Z-100** also inhibited **HIV-1** expression, even when added 24 h after infection. In addition, **Z-100** inhibited the expression of the pNL43lucDeltaenv vector (in which the *env* gene is defective and the *nef* gene is replaced with the *firefly luciferase* gene) when this vector was transfected directly into **MDMs**. These findings suggest that **Z-100** inhibits virus replication, mainly at **HIV-1** transcription. However, **Z-100** also downregulated expression of the cell surface receptors **CD4** and **CCR5** in **MDMs**, suggesting some inhibitory effect on **HIV-1**. Experiments revealed that **Z-100** induced **IFN-beta** production in these cells. **Z-100** induces the production of the 16-kDa **CCAAT/enhancer binding protein (C/EBP)** **beta transcription factor** that represses **HIV-1** long terminal repeat transcription. These effects were alleviated by SB 203580, a specific inhibitor of **p38 mitogen-activated protein kinases (MAPK)**, indicating that the **p38 MAPK** signalling pathway was involved in **Z-100**-induced repression of **HIV-1** replication in **MDMs**. These findings suggest that **Z-100** might be a useful immunomodulator for control of **HIV-1** infection.

Information Extraction Workflow



Why Text-Mine?

- **Curation**
Support construction of high quality knowledge bases
- **Search**
Let users find specific information faster
- **Biomedical Research**
Provide background information for specific types of biomedical analysis (network / systems biology)

Some WBI Projects

- [EUMed](#): Genotype-phenotype relations
 - Mutations, genes, diseases, drugs, mutation-disease, DDI, ...
- [CellFinder](#): Genes characteristic for a given cell
 - Genes, cells, cell lines, transcription, location, function
- [OncoPath](#): Regulatory relationships between TF
 - Genes, species, methods, regulation
- [Virtual Liver](#): Metabolic reactions
 - Chemicals, quantities, units, reactions, methods
- [ColoNet](#): Mammalian clock genes and the clock network

Topics Today

- Named Entity Recognition
- Applications in Curation
- Application in Search

Detecting Gene Names


The human T cell leukemia lymphotropic virus type 1 Tax protein represses MyoD-dependent transcription by inhibiting MyoD-binding to the KIX domain of p300.

The human T cell leukemia lymphotropic virus type 1 Tax protein represses MyoD-dependent transcription by inhibiting MyoD-binding to the KIX domain of p300.

State-of-the-Art Solutions

- Example: GNAT
 - Large dictionaries, 2nd order CRF
 - Species disambiguation using Linnaeus (NER again)
 - Background [texts describing genes](#) and their function
 - Single sense per discourse: Further appearances in the same text
 - No resolution of type and splice variants
- Evaluated performance: ~85% F1-measure
 - Only measured on abstracts, full texts are different
 - Correctness is in the eye of the beholder
 - Different results on different corpora
 - Different quality per species

What Bio-TM People Study (Neves 2014)



What is included here?

In the table below you can find a list of the corpora included here with the respective links to the datasets in STAV. For more information about each corpus, click on the name of it.

DATASETS	VISUALIZATION	LINKS	DOWNLOADS
AIMed	corpus	BioTfX	BioC
protein-protein interactions *	the training corpus was splitted in groups of 40 sentences	BioTfX [license]	(soon)
BioCreative 2 Gene Mention task	gene and protein mentions	BioTfX [license]	(soon)
BioInfer	corpus	BioTfX	BioC
protein-protein interactions *			
BioNLP 2009 Shared Task on Event Extraction	training and development	BioTfX [license]	(soon)
biological events, such as gene expression, regulation, phosphorylation, etc.			
BioNLP 2011 Shared Task	[GE] GENIA: training and development	BioTfX [license]	BioC
	[EPI] Epigenetics and Post-translational Modifications: training and development	BioTfX [license]	BioC
	[ID] Infectious Diseases: training and development	BioTfX [license]	BioC
	[REL] Entity relations: training and development	BioTfX [license]	(soon)
BioText	the corpus was splitted in groups of 40 sentences	BioTfX	(soon)
disease and treatment relationships			
CellFinder 1.0	full text and split by sections	BioTfX [license]	BioC
entities related to the stem cell domain			
Data Deposition	training corpus splitted in groups of 20 sentences	BioTfX	(soon)
statements of data deposition			
Drug-Drug Interaction Extraction 2011 First Challenge	training corpus	BioTfX	BioC
Drug-Drug Interaction Extraction 2013 Second challenge (tasks 9.1 and 9.2)	Medline training corpus	BioTfX	(soon)
	DrugBank training corpus	BioTfX	(soon)

WBI Corpus Repository:
<http://corpora.informatik.hu-berlin.de/#news>

Experiences: NER+NEN


- No true applications without **normalization**
 - ChemSpot2 includes OPSIIN
- Every entity type requires a mid-size project
 - **Training data**, annotator recruitment, domain-specific features, etc.
- In general: The more concrete, the easier
 - Species names versus gene function
- Evaluation usually is a nightmare
 - “The **human** FGD-3' **protein** is soluble in **water** at ...”
 - w/o “protein”, w/o splice variants, w/o taxa, w/o water, ...

Topics Today

- Named Entity Recognition
- Applications in Curation
- Application in Search

Gene-Regulatory Relationships


- Many published “PPI” actually are derived from co-expression, in-silico predictions, phylogenetic inference, ...
- Essential information: **Strength of experimental evidence?**
- Example: Gene regulation and transcription factors



Source: <http://apt.bea.ki.se>

Showing that a TF X **directly** regulates gene Y

TF X **must bind** to the promoter region of gene Y





Presence of TF X
must change
expression of
gene Y


Destroying the promoter
where X binds must change
expression of gene Y

Towards a Human TF Network (Thomas et al. 2015)

- Human: ~1200 TFs
- Only ~500 TF-TF relationships are publically available
 - Transfac, ORegAnno, TRRD
- TM-REG: Enhance human TF core network
 - Identification of potential TF-TF relationships using text mining
 - Manual verification by biological experts
 - Distinguish hypothetical from proven relationships



Workflow



Top-Scores

- Ranking is crucial to use **human time effectively**




Fig. 4. Precision of our workflow for the n most confidently classified and manually curated sentences. Pairs already contained in a regulatory database are ignored (see Table 3).


Results

(Top 2000 sentences, known relationships filtered)

Experimental Evidence	Databases	Curation	All*
<i>Solely one evidence</i>			
-E1 : proof of binding on a DNA-Region	352	39	381
-E2: change in expression upon activation of the TF	0	45	45
-E3: impact of binding site on expression	6	16	22
<i>Exactly two evidences</i>			
-E1 and E2	1	22	24
-E2 and E3	1	17	18
-E1 and E3	108	43	151
<i>All three evidences</i>			
-E1, E2, E3	37	128	170
Total	505	310	815


Table 4. Identified regulatory relationships from the review in comparison to relationships found in common databases and the according experimental evidence.

Specific Pathway: Regulation in Liver



- Black: regulations contained in existing RegDBs;
- Red: added by curation of the top 2,500 unspecific sentences;
- Orange: regulations found by manual curation of all 1,435 sentences with co-occurring liver specific TFs.

Biological Usefulness



- With TM_REG
- Current network
- Randomized

Experiences: Curation

- Key: Combine text mining and human wisdom
 - No way that current text mining techniques can check **evidences at such detail** automatically
- Confidence scores of classifiers do make sense
- High throughput is possible
 - Clear problem setting
 - High performance text mining
 - Appropriate **curation tools**
- Important difference
 - **Fast curation**: Get certain data from all of PubMed
 - **Full curation**: Get everything out of this paper

Manageable

Hard & costly

Topics Today

- Named Entity Recognition
- Application in Curation
- Application in Search

GeneView

- PubMed does not allow searching synonyms of entities
 - “Find mentionings of BRCA1 (170 synonyms)”
- PubMed does not resolve homonyms
 - “Find mentionings of human BRCA1”
- PubMed cannot rank by “semantic” content
 - “Find mutations in BRCA1”
- PubMed does not allow searching for relationships
 - “Find proteins interacting with BRCA1”
- **Geneview does**
 - Free web interface
 - Free database: Annotated PubMed

GeneView

The screenshot displays the GeneView web application interface across multiple browser windows. The main window shows search results for the query "ENTREZ%3A1956&gv_result_order_desc&gv_result_order=DATE&gv_page_size=20&gv_page_size:". The search results list 11 items, including "1. Proteo López-C... Internatio", "2. Ovari Tagawa, J", "3. The R Saldana Journal of", "4. Expre Qi, Ji-ping Breast C", "5. Cigar Russ, R Pulmona", "6. Regu Tamar S Biointerpr", "7. Progr Bailey, C Journal of", "8. Retar Verheije, Advances", "9. Angio Carfa, C Journal of", "10. Mole Peddi, P Internatio", and "11. A Re Kawachi Advances".

The detailed article view for "5. Role of p63 Isoforms in Cancer" is shown in the foreground. The article text discusses the role of p63 isoforms in cancer, mentioning that mutations in the p63 gene are rare in human cancers and that ΔNp63 has oncogenic properties. It also discusses the role of p63 in epithelial development and tumor progression.

The article text includes the following sections:

5. Role of p63 Isoforms in Cancer

Similar to p73, mutations in the p63 gene are rare in human cancers [80, 137, 138]. Several studies reported that ΔNp63 has oncogenic properties. Ectopic overexpression of ΔNp63 in Rat-1A cells promotes colony formation in soft agar. When xenografted into immunocompromised mice, these cells formed tumors [138]. ΔNp63 inhibits oncogene-induced cellular senescence and cooperates with Ras to promote tumor-initiating stem-like proliferation [144]. Analysis of p63-deficient mice led to conflicting results with regard to the p63 role in tumorigenesis. p63^{-/-} null mice showed striking developmental defects demonstrating a critical role of p63 in epithelial development [141, 145]. p63^{+/-} heterozygous mice were shown to be susceptible to tumor development [143]. However, other mouse models were not consistent with this observation. Conflicting phenotypes of TAp63 and ΔNp63 transgenic mice have also been reported [144, 145].

ΔNp63 is a predominant isoform expressed in most epithelial cells. Overexpression of ΔNp63 is found in cancers of nasopharyngeal, head and neck, urinary tract, lung, and ovarian tumors and correlated with poor outcome [78, 146, 149]. In metastases, ΔNp63 expression was found to be reduced or lost [81, 101]. Microarray analyses revealed the up-regulation of genes associated with tumor invasion and metastasis in p63-deficient cells [150]. It was also reported that p63 suppresses the TGFβ-dependent cell migration, invasion, and metastasis [151]. This suggests that ΔNp63 plays a dual role by promoting tumor development but suppressing metastases [151, 152]. Expression of ΔNp63 was found to be associated with an increased chemoresistance in a subset of breast and head and neck tumors [153, 154].

TAp63 isoforms induce cellular senescence and inhibit cell proliferation [155-157]. TAp63 deficiency increases proliferation and enhances Ras-mediated oncogenesis [155]. Decreased TAp63 expression is associated with metastasis in bladder and breast cancers as well as poor outcome [42, 99, 158]. TAp63 impedes the metastatic potential of epithelial tumors by controlling the expression of a crucial set of metastasis suppressor genes [151, 159].

Clearly, additional studies are needed to understand the complex regulation of p63 isoforms.

6. Interplay of p53/p63/p73 Isoforms in Human Cancers

Interactions between members of the p53 family and their isoforms have a profound effect on tumorigenesis and anticancer drug response. Perhaps, the most studied are interactions between ΔN and TA isoforms. Inhibition of TAp73 by ΔNp63 has been shown to negatively affect the response to platinum-based chemotherapy in head and neck squamous cell carcinomas and a subset of breast tumors [153, 154]. In carcinomas of ovary and childhood acute lymphoblastic leukemia, increased expression of dominant-negative p73 isoforms correlates with resistance to conventional chemotherapy [129, 130]. Moreover, ΔNp73 is primarily expressed in ovarian tumors, which express wildtype p53 [64]. However, crosstalk between the p53 family members is not limited to dominant-negative interactions. Accumulating evidence suggests that the p53 family interacts on multiple levels comprising protein-protein interactions between multiple p53, p63, and p73 isoforms, shared regulation of target genes as well as TP53 and TP73 gene promoters [160-163]. In addition, mutant p53 can affect activities of TAp73 and TAp63. It has been shown that certain tumor-derived p53 mutants (R248G, R273G, R281G) can physically associate and inhibit activation of TAp73 and/or TAp63 [164, 166].

Current analyses suggest that the function of a particular isoform needs to be investigated in the context of expression of other isoforms and p53-dependent apoptosis in primary sympathetic neurons [167], but when overexpressed in cancer cells, ΔNp73 induces cell cycle arrest [168].

An interesting observation has been made in mouse embryonic fibroblasts, where the combined loss of p73 and p63 results in the failure of DNA damage [169]. More recent studies have reported that the p53 family members can simultaneously co-occupy the promoters of p53 transcription [15, 170, 171]. Notably, the integral activity of the entire p53 family, as measured by reporter analysis, is a better predictor of chemoresponsiveness than p53 status alone [15].

7. Conclusion

The p53 family plays a pivotal role in the control of many critical cellular functions. In recent years, it has been revealed that all members of the p53 family are expressed as a diverse variety of isoforms. We only just started to uncover the mechanisms that regulate this diversity. A number of studies also provided the first glimpses of their functional significance. Clearly, isoforms add a new level of functional regulation to many critical biological processes including cell death, proliferation, cell cycle control, and tumorigenesis. Depending on the isoform expressed, the role of a gene can dramatically change from a tumor suppressor to an oncogene. It is also clear that p53, p73, and p63 isoforms tightly interact. A better understanding of this interacting network and its regulation holds the key to future therapeutic benefits.

Biomedical IE at Scale

Entity type	Genes	GNAT	of articles
Cell-type	Chemicals	ChemSpot	5,622
Chemical	Species	Linneaus	9,851,536
Disease	SNPs	MutationFinder	74,583
Drugs	Histone-Mod	SETH	6,246,067
Enzyme	Cell type	Banner	590,301
Genes	Disease	(unpublished)	2,959,439
Histone-mod	7,673
SNP			192,544
Species			9,119,134
Tissue			222
Overall			13,463,850

Experiences: Search

- **User interface** more important than 2% more F-measure
- **Errors** are inevitable; sometimes accepted, sometimes not
- Keeping it up-to-date (tools & data) is a challenge
- Users use context you cannot capture (author, journal, ...)
- Much work, few papers
- **Scalability** is a real issue

Acknowledgements

- Philippe Thomas
- Mariana Lara Neves
- Tim Rocktäschel
- Torsten Huber
- Michael Weidlich
- Astrid Rheinländer
- Anja Kunkel
- Martin Beckmann
- Marc Bux
- Jörgen Brandt
- Christine Sers
- Nils Blüthgen
- Bertram KLinger
- Andreas Kurz
- Angela Relogio

